Story

Boston Scientific to Cut Jobs in Restructuring Plan Targeting $500 Million in Annual Savings

ENTHMSVIIDZHZH-TWJAKOHI
Jul 27, 20261 min read
Boston Scientific to Cut Jobs in Restructuring Plan Targeting $500 Million in Annual Savings

Summary

Medical device maker Boston Scientific has approved a multi-year restructuring plan that will involve job losses and cost between $700 million and $800 million, aiming to reduce annual expenses by $500 million upon completion.

Text size
Background

Boston Scientific (NYSE: BSX) has initiated a new company-wide restructuring plan designed to cut costs and streamline operations for future growth, the medical device manufacturer disclosed in a regulatory filing on Monday.

Details of the Restructuring

The plan, which the company's board approved on July 21, will involve significant changes to its global operations. According to the filing, the initiatives include supply chain optimization, shifting some production between manufacturing facilities, and reorganizing its organizational structure.

Boston Scientific expects the restructuring to commence this year and be substantially complete by the end of 2029. The company stated that the changes will result in job losses, though it plans to continue hiring in strategic growth areas and reallocate resources to meet global market demands.

Financial Implications

Sample IUX Markets – In-articleAd

The company projects the plan will incur $700 million to $800 million in pre-tax charges, with an estimated $600 million to $700 million of that total to be paid in cash.

In exchange for this investment, Boston Scientific anticipates achieving approximately $500 million in annual expense reductions once the plan is fully implemented. A significant portion of these savings will be reinvested back into the company's growth initiatives.

Market Context

This announcement comes just ahead of the company's scheduled second-quarter results on July 29. Investors will be closely watching the performance of its heart device portfolio, a key segment for the medical technology firm.

Read next

More on Stocks
Back to latest news

LATEST